StockData

Caribou Biosciences vs X4 Pharmaceuticals

CRBU and XFOR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRBU and XFOR compare

X4 Pharmaceuticals is the larger company, worth 8.4 times as much as Caribou Biosciences ($306M against $36.5M).

X4 Pharmaceuticals grew revenue faster over the last twelve months (73.7% versus 10.0% for Caribou Biosciences).

X4 Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −813% compared with −1030% at Caribou Biosciences.

Caribou Biosciences scores higher on the StockData Score (9 against 3 for X4 Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRBUXFOR
Size and price
Market cap$36.5M$306M
Share price$0.341$3.09
Change, 1 year−82.9%−15.6%
Change, 5 years−98.1%−97.7%
Beta (5Y)1.411.45
Employees9745
StockData Score
Total score9 (better)3
Valuation score3 (better)0
Growth score12 (better)
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S3.6× (better)30.9×
P/B0.4× (better)2.2×
FCF yield−262%–
Fair value$1.29–
Margin of safety73.7%–
Growth
Revenue growth (TTM)10.0%73.7% (better)
Revenue growth, 5Y average−2.0%16.7% (better)
Profitability
Gross margin–68.8%
Operating margin−1091%−812% (better)
Net margin−1030%−813% (better)
FCF margin−954%–
Return on equity−78.3% (better)−80.3%
Financial health
Debt / equity0.00–
Interest coverage–−9.3×
Current ratio6.4913.22 (better)
Altman Z-score−7.47−2.11 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Buyback yield−66.3%–
Shareholder yield−66.3%0.00% (better)
Ownership
Held by institutions45.5%103%
Held by insiders5.7%12.2%
Insider net buying, 12 months−$47.5K (better)−$451K
Short interest, % of float14.7%9.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.